Aging
Navigate
Submit an Article
Research Paper|Volume 13, Issue 3|pp 3957—3968

Gene signatures of 6-methyladenine regulators in women with lung adenocarcinoma and development of a risk scoring system: a retrospective study using the cancer genome atlas database

Chundi Gao1, Jing Zhuang2, Huayao Li3, Cun Liu1, Chao Zhou2, Lijuan Liu2, Fubin Feng2, Changgang Sun2,4
  • 1College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong, PR China
  • 2Departmen of Oncology, Weifang Traditional Chinese Hospital, Weifang 261041, Shandong, PR China
  • 3College of Basic Medical Sciences, Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong, PR China
  • 4Cancer and Immunology Institute, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, PR China
* Equal contribution
Received: July 15, 2020Accepted: November 23, 2020Published: January 10, 2021
https://doi.org/10.18632/aging.202364

Copyright: © 2021 et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Although the emergence of new treatments has improved the prognosis of women with lung adenocarcinoma (LUAD), the emergence of drug resistance limits their clinical efficacy. Therefore, there is an urgent need to identify new targets and develop a risk scoring system to evaluate the prognosis of patients. 6-methyladenine (M6A), as the most common methyl modification in RNA modification, its clinicopathological features, diagnosis and prognostic value in lung cancer, especially in LUAD remain to be discussed. We analyzed the clinical and sequencing data of the female LUAD cohort from The Cancer Genome Atlas (TCGA), evaluated the expression profiles of 16 M6A regulation-related genes in the cohort and the relationships between genetic changes and clinical characteristics, developed an M6A-related risk scoring system using Cox analysis. Finally, the copy number variations (CNVs) of the related genes in the samples were analyzed and verified using the cBioPortal platform. Compared with other clinical factors, this risk scoring system showed a higher predictive sensitivity and specificity. The M6A-related risk scoring system developed in this study may help to improve the screening of female patients at high risk of LUAD and provides important theoretical bioinformatics support for evaluating the prognosis of such patients.